Curcumin
Curcumin is the primary bioactive polyphenol in turmeric (Curcuma longa) with extensive preclinical evidence but historically disappointing clinical results due to poor bioavailability (~1% of standard curcumin is absorbed). Bioavailability-enhanced forms (BCM-95, Meriva, Longvida, theracurmin) overcome this and show strong clinical evidence for: osteoarthritis pain reduction (comparable to ibuprofen), reduced systemic inflammation (CRP, IL-6, TNF), cognitive function in mild cognitive impairment, and depression adjunct therapy. Multiple mechanisms converge on NF-kB inhibition. Use standardized, enhanced-bioavailability forms exclusively — plain curcumin powder is largely ineffective.
Evidence
No score yet
Safety
Unknown safety profile
Clinical Status
No formal phase listed
Research Sync
Not synced yet
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Plain-English Snapshot
Curcumin is currently categorized as a supplement compound.
Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
IKKβ inhibition → NF-kB nuclear translocation block; COX-2 and 5-LOX inhibition; Nrf2 activation; AMPK activation; reduces TNF-alpha, IL-1beta, IL-6
Practical Context
Strongest current signals
No indexed study summaries yet.